Skip to main content

Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT-TMA: Results of a Phase 3 Trial

In brief

Ravulizumab-treated children with transplant-related microangiopathy had 73% estimated one-year survival

In a single-arm trial of 41 children with transplant-related thrombotic microangiopathy, estimated survival was 73.4% at 52 weeks; 17% achieved complete response and 54% partial response. Most improved in at least one disease marker, and no new safety signals emerged. Without a comparison group, the trial cannot show how much ravulizumab contributed to survival or improvement.

Journal
American journal of hematology (Q1)
Published
13 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Franco Locatelli, Michelle L Schoettler, David Bueno-Sánchez, Sonali Chaudhury, Jude Fry, Eric Bachman, et al.
PMID
43025899
DOI
10.1002/ajh.70545

Why clinicians should know about it

  • Picked for Hematology (paper of the day, 15 November 2026): Phase III treatment trial for life-threatening transplant-associated TMA

Abstract

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a rare, life-threatening complication that can lead to multiorgan failure and death. The ALXN1210-TMA-314 global, Phase 3, open-label, single-arm trial evaluated ravulizumab, a C5 inhibitor, for treatment of HSCT-TMA in children (NCT04557735). Eligible participants aged ≥ 28 days to < 18 years had HSCT-TMA within 12 months from HSCT, which persisted for ≥ 72 h despite initial management. Participants received weight-based ravulizumab plus best supportive care during the 26-week treatment period, followed by a 26-week follow-up period. The protocol-defined primary endpoint was complete TMA response during the treatment period. Key secondary endpoints included individual TMA response components (proteinuria, platelets, and lactate dehydrogenase/schistocytes), overall survival (OS), and safety. Of 41 enrolled participants (mean age, 7.6 years; 51.2% female), 28 (68.3%) completed treatment, and 24 (58.5%) completed the study. Through the treatment period, 7 (17.1%) participants achieved complete TMA response, and 22 (53.7%) achieved partial TMA response; 29 (70.7%) participants achieved improvement in ≥ 1 TMA response component. Estimated OS was 92.6% at Day 100, 87.2% at Week 26, and 73.4% at Week 52. During treatment, a low incidence of serious TEAEs was assessed by investigators as related to ravulizumab (3 participants, 7.3%); no new safety signals were identified. No meningococcal infections were reported. In this global Phase 3 trial in children with HSCT-TMA, ravulizumab treatment resulted in excellent OS and normalization of early laboratory markers of TMA in many patients. TRIAL REGISTRATION: NCT04557735.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.